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Abstract
a-synuclein (aS) is a cellular protein mostly known for the association of its aggregated forms with a variety of diseases that
include Parkinson’s disease and Dementia with Lewy Bodies. While the role of aS in disease is well documented there is
currently no agreement on the physiological function of the normal isoform of the protein. Here we provide strong
evidence that aS is a cellular ferrireductase, responsible for reducing iron (III) to bio available iron (II). The recombinant form
of the protein has a VMax of 2.72 nmols/min/mg and Km 23 mM. This activity is also evident in lysates from neuronal cell lines
overexpressing aS. This activity is dependent on copper bound to aS as a cofactor and NADH as an electron donor.
Overexpression of a-synuclein by cells significantly increases the percentage of iron (II) in cells. The common disease
mutations associated with increased susceptibility to PD show differences in activity or iron (II) levels. This discovery may
well provide new therapeutic targets for PD and Lewy body dementias.
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Introduction
The 140 residue presynaptic protein a-synuclein (aS) has been
implicated in the pathogenesis of several neurodegenerative
disorders including Parkinson’s disease (PD), Lewy body variant
Alzheimer’s disease and dementia with Lewy bodies (DLB) [1].
The symptoms of these conditions result from a loss of
dopaminergic neurons, primarily from the pars compacta region
of the substantia nigra. This then leads to a disruption of activity in
basal ganglia that govern movement. Accompanied with these
symptoms is an accumulation of ubiquitin bound aS within
diseased cells [2]. The precise mechanism by which this is related
to cell death remains unknown. Furthermore, a key issue in the
fight against Lewy body disorders is that the physiological function
of aS remains unknown, although it is thought to be related to
membrane binding [3].
It has previously been suggested that aS is a copper binding
protein[4]. Other studies have revealed a potentially significant
association with iron [5,6]. This factor may provide insight into its
function as many proteins that bind redox active metals ions such
as copper have a catalytic role. Previous investigations into the
coordination of copper and iron binding to aS have failed to reach
a consensus. Initial results showed aS to bind 5–10 molecules of
copper [7,8] while a later study showed aS to bind copper at two
high affinity sites with more copper able to bind at other lower
affinity sites [4]. A more recent study found two, independent,
non-interacting Copper (II) binding sites in the N-terminus of aS
[9].
The function of aS has often been suggested to be associated
with dopamine metabolism and a variety of data indicate changes
to dopamine synthesis, storage and transport processes[10]. In
particular, a number of studies have suggested that overexpression
of aS alters the activity of the key enzyme involved in dopamine
synthesis, tyrosine hydroxylase[11,12]. Dopamine synthesis in aS-
knockout mice is reduced.[13]. Parkinson’s disease shows changes
to brain iron including the ratio of Fe(II) and Fe(III)[14]. Fe(II) is
necessary for dopamine synthesis as it is a co-factor of tyrosine
hydroxylase. Fe(III) may induce oxidative stress through interac-
tion with neuromelanin [15]. Therefore, regulation of the ratio of
Fe(II) to Fe(III) might be important for the survival of
dopaminergic neurons. However, all these suggestions are
inferential and no direct observation of a function has been made
so far.
Our investigations of metal binding to aS lead us to investigate
the potential of this interaction to endow function to the protein
that might be relevant to the maintenance of Fe(II) levels in cells.
Our findings demonstrate conclusively that aS is a ferrireductase.
Results
Metal Binding
We first assessed the copper (II) and iron (III) binding to aSi n
order to gain insight into the significance of this association.
Recombinant aS was cloned from human cell lines and expressed
and purified by a method developed by our laboratory.
Thermodynamic analysis using isothermal titration calorimetry
(ITC) was used to assess the Cu(II) and Fe (III) binding dynamics
of the protein. Figure 1 shows a representative isotherm for the
delivery of glycine chelated copper (II) and unchelated iron (III) to
aS. A titration of Fe (III) into Cu (II) loaded aS was also carried
out. The isotherm for Copper (II) shows a net endothermic
reaction as a result of the high enthalpy of copper disassociation
from glycine. The overall effect of the glycine chelate on the
isotherm was accounted for as previously described [16]. The
fitting of a non-linear regression model (Microcal) to the data to
the isotherm for Cu (II) revealed one binding site, with affinity of
log 9.43 M
21. The titration of iron (III) into aS produced an
exothermic reaction suggesting two binding sites (Figure 1). The
affinity of Fe(III) for the protein was for log 5.02 M
21 both sites. A
titration of iron (III) into protein that has been allowed to
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reaction. The reaction indicated two sites with a affinity of log
4.50 M
21. Although the affinity at the sites was reduced the data
indicated that aS can bind both copper and iron simultaneously.
This then led us to hypothesise that copper loaded aS may be
catalysing a redox process with the iron, perhaps reducing it to the
ferrous form.
Ferrireductase Activity in Recombinant Protein
In order to assess whether aS displayed ferrireductase activity,
we used recombinant protein for an assessment of precise enzyme
kinetics. The copper (II) bound protein was subjected to a
ferrozine ((3-(2-pyridyl)-5,6- bis(phenyl sulfonic acid)-1,2,4-tri-
azine), based assay to detect the reduction of iron (III) to iron
(II), using NADH as an electron donor. Ferrozine forms a bis
complex which is highly specific to the ferrous form of the ionic
metal [17] and adsorbs light strongly at 562 nm. Figure 2(i) shows
a linear plot of standard Fe
2+ against absorbance for the
determination of ferric iron concentrations. The ferric iron was
added anaerobically as Fe (II) sulphate. For the assessment of aS
ferrireductase activity Fe (III) was added as iron citrate. Controls
in the absence of copper, protein or NADH were used to ensure
any observed activity was due to the copper loaded protein.
Figure 2(ii) shows the plot of the A562 against time for this
experiment. For the copper loaded protein in the presence of
NADH, concentrations of 20 mM and 30 mM Fe (III) citrate are
shown. From the plot, it is clear that aS is able to catalyse the
reduction of iron (III) to iron (II) in the presence of NADH and
that this is dependent on the protein being loaded with copper (II).
Increasing the concentration of substrate increases the rate of
reaction in a predictable manner. Experiments were carried out
with a range of substrate concentrations from 1 mM to 100 mM
iron (III). Figure 2(iii) shows a plot of Vo against substrate
concentration and figure 2(iv) shows a double reciprocal plot of
this data. From these plots, the Vmax and Km can be calculated for
the reaction (table 1). Certain gene mutations have been associated
with an increased risk of PD [18] and as such these mutants were
generated and tested to assess any affects on the ferrireductase
activity of the protein. Figure 3 shows the double reciprocal plots
for this data. From the plot, it is clear there is a small but
significant affect on the activity of the protein. Table 1 summarises
the key kinetic data obtained. We also analysed the homologue of
aS, beta-synuclein (bS) but this protein had no activity in this assay
(data not shown) suggesting the ferrireductase activity is specific to
aS.
aS Increases Cellular Ferriductase Activity and Fe(II)
Levels
With data obtained from recombinant protein, there is clearly a
need to investigate whether cellular forms behave in a similar way.
As such, we also transfected human neural cell lines with aS and
its disease associated mutants to overexpress the protein in a cell
culture based system. Lysates were then prepared and equal
quantities of protein, assessed by Bradford assay and western blot,
were assayed under identical conditions to those before. Figure 4(i)
shows a plot of the A562 against time for the assay on the lysates
from cells normally expressing aS and overexpressing the protein
and its disease associated mutants. Figure 4(ii) shows the calculated
initial rates form the experiment. There is a significant increase in
ferrireductase activity in all the conditions using lysates from cells
overexpressing aS when compared to lysates from cells normally
expressing the protein. There was also a significant increase in
activity in the lysates from cells overexpressing the E46K mutant.
This suggests that this disease mutant behaves differently to
normal aS with respect to its enzymatic activity in cells.
In order to verify that increased cellular ferrireductase activity
resulted in an increase in reduced iron in cells overexpressing aS
or its mutants, the levels of ratio of Fe(II) total cellular Fe was
determined for the stable cell lines using a commercial kit. The
ratio of Fe(II) to total Fe is shown in Figure 5. As can be seen,
overexpression of aS resulted in a significant increase in the
proportion of Fe(II) present in the cells (Student’s t test p,0.05).
The three mutants of aS also showed significant increases but
there was no significant difference between any of the mutants and
wild-type aS. In contrast bS overexpression caused a small but
significant decrease in the levels of Fe(II). This result indicates that
the increase in Fe(II) is the result of overexpression of a protein
with ferrireductase activity.
Figure 1. ITC analysis of copper and iron binding. ITC traces for titrations of Cu (II) or Fe (III) into 100 mM aSa tp H7 ,2 5 uC. An isotherm for the
titration of Fe (III) into Cu (II) loaded protein is also shown (far right).
doi:10.1371/journal.pone.0015814.g001
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While the associationofaS witha numberofdiseaseshasresulted
in the expression ‘‘synucleinopathies’’ to describe them, the exact
role of this protein in disease pathogenesis is poorly understood[19].
A potential avenue of investigation to identify the mechanism would
be to identify the function of the protein and then establish how this
activity is lost or altered in diseases such as Parkinson’s disease.
There have been a number of suggestions about the possible
function of aS but none have been conclusively accepted[20]. The
lossofdopaminergicneuronsinParkinson’sdiseasehasleadtosome
efforts in linking aS to some aspect of dopamine metabolism such as
vesicular release[21]. The data presented here represents the first
suggestion of an enzymatic activity for aS that could be of relevance
for dopaminergic cells. This function also takes into account the
metal binding capacity of the protein.
While analysis of copper binding to aS has been relatively
extensive[4,22,23,24,25,26,27], there has been little consideration
Figure 2. Kinetic plots of the ferrireductase activity of aSa t2 5 6C. (i) Ferrozine calibration curve for standards of Fe (II) sulphate monitored at
562 nm. (ii) The change in absorbance for formation of ferrozine – Fe (II) complex at 562 nm for aS with either 20 mM or 30 mM Fe (III) and controls
missing either protein, copper or NADH. (iii) Initial rates of activity dependent on substrate concentration. (iv) Double reciprocal plot for the
calculation of Vmax and Km.
doi:10.1371/journal.pone.0015814.g002
Table 1. Comparison of the kinetic parameters for the
ferrireductase activity of aS and its disease associated
mutants.
Mutant Vmax (nmols/min/mg) Km (mM)
Wildtype 2.72 23
E46K 2.52 23
A30P 2.37 19
A53T 2.62 25
Assays recorded at 562 nm and 25uC.
doi:10.1371/journal.pone.0015814.t001
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bind iron but demonstrate that this may be important for the
normal activity of the protein. Differences in the affinity values
report by us when compared to others in the literature probably
reflect methodological differences. In particular we show a single
copper binding site while others report two sites[4]. The use of
chelators in our studies eliminates non-specific interaction and
maintains copper in a more physiological form than those who use
free copper. Also, MOPS is a buffer with significantly low
interference with thermodynamic equilibria ensuring that our
measurements are related only to metal-protein binding events. A
single copper binding site has been reported by others using ITC
and our data confirms their findings. In relation to iron our
experiments were performed under conditions that resulted in little
or no precipitation of Fe and the higher affinity we observe reflects
this.
Figure 3. Comparison of the ferrireductase activity of the disease associated aS mutants.
doi:10.1371/journal.pone.0015814.g003
Figure 4. Cellular Ferrireductase Activity. Ferrireductase activity of lysates from neuronal cells normally or over expressing aS and its disease
associated mutants. (i) The change in absorbance for formation of ferrozine – Fe (II) complex at 562 nm. (ii) A comparison of the initial rates.
doi:10.1371/journal.pone.0015814.g004
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simultaneously. Cu(II) saturate aS was still able to bind Fe(III) with
little change in affinity. This clearly indicates that the two metals
occupy different sites on the protein. The majority of data suggest
that copper binds to the N-terminus of aS while iron binds to the C-
terminus. This finding would alsosuggestthat thereisa differencein
theco-ordination ofthe metals.Some studieshavesuggested that aS
can bind more copper than we have shown with ITC. Under these
conditions copper binding might prevent iron binding at one or
more sites. However, as previously suggest, replacement of iron by
copper, and binding of copper at multiple sites on the protein might
lead to aggregation of the protein. The potential of copper to
enhance aS aggregation has been observed. In contrast, our
suggestion is that both copper and iron can bind to the protein
under normal physiological conditions and allow it catalyse the
reduction of Fe(III) to Fe(II), indicative of a ferrireductase.
The data presented here suggests that aS is able to function as a
cellular ferrireductase. This ties in well with recent evidence
showing the protein associated with cell membranes [3]. Most
cellular ferrireductases are found integral or closely associated to
the bio-membrane [28]. Also, ferrireductases commonly utilise
redox cycling of copper atoms to remove electrons from iron and
thus reduce Fe(III) to Fe(II). The data we present shows kinetics
that fit well with a simple enzyme following a Michaelis-Menten
model. The activity requires an electron acceptor such as NADH
and does not occur in the absence of copper. Significantly, the
activity was observed with both recombinant protein and in cells
overexpressing aS. Increased Fe (II) levels in the cell confirm that
the ferrireductase assay measured a reduction process.
Our findings on aS activity are possibly important for
understanding its cellular role. However, a key reason for studying
aS is its role in diseases such as Parkinson’s Disease. In Parkinson’s
disease the important change that occurs is the loss of
dopamingeric neurons. When considering the potential role of a
ferrireductase in dopaminergic cells then the generation of
increased levels of Fe(II) may be important. A key enzyme in the
dopamine pathway is tyrosine hydroxylase (TH) [29], an iron (II)
dependent hydroxylase responsible for catalyzing the conversion of
the amino acid L-tyrosine to dihydroxyphenylalanine (L-DOPA).
Disruption of this pathway would occur if bio available Fe (II) was
reduced as a result of a reduction of ferrireductase activity.
Additionally, there is a build up of iron (III) in dopaminergic
neurons in patients suffering from PD [30]. Clearly, a key
pathological feature of Lewy body dementia is the aggregation of
aS. It is reasonable to assume that aggregated protein would lose
any enzymatic activity and hence have an affect on the ability of
the cell to produce bio-available iron (II). Alternatively, increased
expression of aS as occurs in Parkinson’s disease may generate
excess Fe(II) a metal that can catalyse the Fenton reaction and
generate excess reactive oxygen species which may result in
apoptosis. While these considerations are highly speculative, it
does clearly indicate potential mechanisms where by altering
ferrireductase activity could have a significant impact on the
survival of dopaminergic neurons.
aS mutants identified from inherited forms of Parkinson’s
disease were also studied for their impact on Ferriductase activity
and iron reduction. There was little evidence that these point
mutations had any significant effect on this activity. This does not
preclude the possibility that alterations in ferrireductase activity
could be important for dopaminergic neuron survival. Partients
with inherited forms of Parkinson’s disease live a significant part of
their lives without developing symptoms but have an earlier onset
of symptoms than seen in sporadic. Therefore it is likely that these
mutations have their impact in concert with age dependent
changes. Thus a gross alteration of protein function is unlikely and
has been confirmed by these findings.
In summary we have identified aS as a cellular ferrireductase.
This provides the first finding of a function for this protein via
direct observation rather than inference. Given the importance of
maintaining Fe(II) levels in dopaminergic cells, this activity is likely
to be of considerable importance to understanding the changes
that occur in dopaminergic cells leading to their selective loss in
Parkinson’s disease.
Methods
All reagents were purchased from Sigma unless otherwise
stated.
Recombinant Protein
aS and bS were produced as previously described [31] with the
exception that the ammonium sulphate precipitation step was
Figure 5. Iron Content of Cells. The levels of Fe(II) as compared to total cellular Fe (Fe(II)+Fe(III) in cell lines were assessed using a commercial
assay. The cell lines were stably tranfected with either pCDNA, aS, the three aS mutants or bS. As a control the parental SH-SY5Y (SH) cell line was also
analysed. Shown are the mean and standard error for three individual experiments with triplicate analyses.
doi:10.1371/journal.pone.0015814.g005
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filtered water to a 1,000,000 times. Site directed mutagenesis was
employed to create the disease associated mutants A30P, E46K
and A53T of aS as previously described [16] using primers
produced by MWG, Germany.
Cell Culture
SH-SY5Y (human neuroblastoma) cells were cultured in 50%
(v/v) Dulbecco’s Modified Eagle Media and 50% (v/v) Ham’s F-
12 supplemented with 10% (v/v) fetal bovine serum (FBS), 100 U/
ml penicillin, 100 mg/ml streptomycin and 2 mM glutamine. All
the media and reagents were obtained from Biowhittaker Lonza.
Growth conditions were maintained at 37uC and 5% CO2 in a
humidified incubator.
Transfections
Wildtype bS, aS and its disease associated mutants were
subcloned into pcDNA plasmid transfected using FuGene 6
transfection reagent (Roche applied science). For stable transfec-
tions, 6-well plates were used and cells were plated at 50%
confluency the day before the transfection. To perform the
transfection 50 ml of serum free media was transferred into a
micro-centrifuge tube; 3 ml of the FuGene 6 reagent was then
added directly to this and mixed by gentle flicking. The mixture
was incubated for 5 minutes at room temperature. For each cell
line, 1 mg of DNA was then added to the mixture, mixed as before,
and incubated at room temperature for 15 minutes. After this the
transfection mixture was added to the cells, the 6-well plate swirled
and returned to the incubator overnight. Cells were selected with
400 mg/ml G418 sulfate (Calbiochem) 24 hours after transfection,
and maintained in 100 mg/ml to keep the plasmid in the cells.
Isothermal Titration Calorimetry
ITC was carried out as previously described [16]. Various
concentrations of protein were titrated with Cu (II): Glycine in a
1:2 ratio to a final molar ratio of 1: 5. All solutions were buffered in
50 mM MOPS (3-(N-Morpholino)propanesulfonic acid) pH 7.
For analysis of Fe(III) binding, aS was prepared at 250 mM and
titrated with iron citrated 12.5 mM. Analysis of Fe(III) binding to
copper saturated aS was also performed. In this case the aS was
incubated with two molar equivalents of CuSO4 prior to ITC
experiments.
Ferrireductase Assay
Protein solutions of standardised cell lystates or to a final
concentration of 100 mM recombinant protein were mixed with
final concentrations of 100 mM ferrozine ((3-(2-pyridyl)-5,6-
bis(phenyl sulfonic acid)-1,2,4-triazine), 50 mM NADH, 100 mM
MOPS pH 7. Protein had been exposed to 4 equivalents of copper
(II) sulphate and allowed to equilibrate. The reaction was started
by the addition of iron (III) citrate to final concentrations between
1 mM and 100 mM to a final reaction volume of 100 mL. Reactions
were carried out in 96 well plates and monitored at 562 nm in a
BMG flurostar. All conditions wee repeated at least 8 times.
Iron Assay
Levels of Fe(II) and total Fe were analysed in cell lines using the
kit from Abcam and following the manufacturer’s instructions.
Cells were harvested from a confluent T75 for each analysis.
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